Epica International, Inc.
For almost 5 years, Epica International has been working with a multi-disciplinary team of top surgeons, imaging and robotic technologists to develop and launch the highest resolution mobile multi-modality robotic imaging platform available. Our hybrid imaging platform is diagnostic (in soft and hard tissue), interventional and intraoperative. Our imaging and surgical assist robotic platforms offer superior image resolution and precision at less cost than conventional multi-slice CT systems and disassociated surgical robots.
What started as a multidisciplinary team focused on the development of an alternative to the shortcomings of conventional CT imaging led to the development of a non-interpolated diagnostic and intraoperative imaging platform capable of identifying sub 1mm lesions and anatomies as small as the vasculature of a hummingbird with less radiation dose and cost, has evolved into 28 issued patents, 47 pending patents, 225 imaging platforms sold, and now our first human medical imaging platform (FDA 510k and CE pending). Further, we have mechanically linked our medical imaging platform and proprietary surgical assist robot providing the surgeon with an ability to see more and operate with greater therapeutic precision.
The future of medicine—the integration of non-contact imaging (CT) and physician assisting robotics.
Epica, the Robotic CT Company.
OUR VISION
As a global leader in precision robotics and imaging platforms, Epica International designs, develops and distributes progressive robotic systems that guide and assist users, ensure accuracy and strengthen outcomes. By fusing CT imaging and precision robotics into one fully integrated platform, we deliver diagnostic and therapeutic applications for optimal therapeutic outcome.
NEWS
Learn about the latest research, developments, and trends from Epica International's Companies and Customers.
